N-tert-butoxycarbonyl-L-seryl-L-glutamic acid 1-methylamide 5-benzyl ester | 190586-72-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert-butoxycarbonyl-L-seryl-L-glutamic acid 1-methylamide 5-benzyl ester
• 英文别名: Boc-Ser-Glu(OBn)-NHMe；benzyl (4S)-4-[[(2S)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-5-(methylamino)-5-oxopentanoate
• CAS: 190586-72-2
• 化学式: C₂₁H₃₁N₃O₇
• 分子量: 437.493
• InChiKey: QWQMANZQPYBCAM-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  143
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-tert-butoxycarbonyl-L-seryl-L-glutamic acid 1-methylamide 5-benzyl ester 在 4 A molecular sieve 、 silver trifluoromethanesulfonate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 tin(ll) chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.5h， 生成 -L-glutamic acid 1-methylamide 5-benzyl ester
  参考文献：
  名称：

  Studies on Selectin Blockers. 7. Structure−Activity Relationships of Sialyl Lewis X Mimetics Based on Modified Ser-Glu Dipeptides

  摘要：

  We have previously found that heterochiral fucodipeptides, L-Ser-D-Glu (3a) and D-Ser-L-Glu (3b), exhibited up to 20-100 times more potency than a sialyl Lewis X (sLe(x), 1) and a 3'-sulfated Lewis X analogue (2) toward E-selectin binding and have also proposed, from molecular dynamics calculation, that their strong activities would depend on a possible formation of the type II and/or type II' beta-turn of compounds 3a,b (Tsukida, T.; Hiramatsu, Y.; Tsujishita, H.; Kiyoi, T.; Yoshida, M.; Kurokawa, K.; Moriyama, H.; Ohmoto, H.; Wada, Y.; Saito, T.; Kondo, H. J. Med. Chem. 1997, 40, 3534-3541). To clarify our hypothesis, we synthesized several analogues of compounds 3a,b and investigated their structure-activity relationships. As a result, it was indicated that the type II and/or type II' beta-turn conformation would be a comparatively tight form and would play important roles in favorable binding to E-selectin. These findings indicate that sLe(x) mimetics with type II and type II'-beta-turn dipeptides could be a useful methodology for the design of an active selectin blocker.

  DOI：

  10.1021/jm980267x
• 作为产物：
  描述：

  benzyl N-tert-butyloxycarbonyl-L-γ-glutamate α-N-methylamide 在 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 N-tert-butoxycarbonyl-L-seryl-L-glutamic acid 1-methylamide 5-benzyl ester
  参考文献：
  名称：

  关于选择阻滞剂的研究。5.基于修饰的丝氨酸-谷氨酸二肽的唾液酸化的Lewis x模拟物的设计，合成和生物学特征。

  摘要：

  我们基于分子模型合理设计了sLe（x）模拟物，合成了II型和II'型β-转二肽（3a，b），并在体外和体内评估了它们的生物学特性。针对E-选择素-sLe（x）结合，II型β-转二肽L-Ser-D-Glu 3a（IC50，13 microM）和II'β-转二肽D-Ser-L-Glu 3b（ IC50（5.5 microM）比sLe（x）（1; IC50，600 microM）和3'-硫酸化Le（x）类似物（2; IC50，280 microM）强效阻滞剂高20-100倍。另一方面，其他立体异构体（例如L-Ser-L-Glu 3c和D-Ser-D-Glu 3d）是非常弱的阻滞剂，3c，d的IC50> 1000 microM。相对于P-和L-选择素，尽管化合物3a-d的立体化学差异很大，但二肽3a-d的阻滞剂均比sLe（x）或化合物2强。在小鼠模型中，化合物3b提供了针对免疫球蛋白E介导的皮肤反

  DOI：

  10.1021/jm970262k

文献信息

• FUCOSE DERIVATIVES, DRUGS CONTAINING THE SAME AS ACTIVE INGREDIENT, AND INTERMEDIATES FOR PRODUCING THE SAME
  申请人：KANEBO, LTD.

  公开号：EP0859005A1

  公开（公告）日：1998-08-19

  A compound of the formula (I): wherein X1 is a group of one of the following formulae (1), (2) and (3): R1 is a branched long chain alkyl group, R2 is ―CONHR3, a carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and R3 is a lower alkyl group or a phenyl group, or a pharmaceutically acceptable salt thereof, which is useful as a selectin inhibitor, and can be used in the prophylaxis or treatment of various inflammatory diseases such as inflammatory dermatitis (e.g., atopic dermatitis, contact hypersensitivity, photodermatosis, etc.), autoimmune chronic diseases (e.g. rheumatoid arthritis, chronic thyroiditis, etc.), and ischemia-reperfusion injury.

  式 (I) 的化合物： 其中 X1 是下式（1）、（2）和（3）之一的基团： R1是支链长链烷基，R2是-CONHR3、羧基或氢原子，n是0、1或2的整数，R3是低级烷基或苯基，或其药学上可接受的盐，可作为选择素抑制剂，用于预防或治疗各种炎症性疾病，如炎症性皮炎（如、特应性皮炎、接触性过敏、光敏性皮肤病等）、自身免疫性慢性疾病（如类风湿性关节炎、慢性甲状腺炎等）以及缺血再灌注损伤。
• US5919769A
  申请人：——

  公开号：US5919769A

  公开（公告）日：1999-07-06
• Studies on Selectin Blockers. 7. Structure−Activity Relationships of Sialyl Lewis X Mimetics Based on Modified Ser-Glu Dipeptides
  作者：Takahiro Tsukida、Hideki Moriyama、Kiriko Kurokawa、Toshio Achiha、Yoshimasa Inoue、Hirosato Kondo

  DOI：10.1021/jm980267x

  日期：1998.10.1

  We have previously found that heterochiral fucodipeptides, L-Ser-D-Glu (3a) and D-Ser-L-Glu (3b), exhibited up to 20-100 times more potency than a sialyl Lewis X (sLe(x), 1) and a 3'-sulfated Lewis X analogue (2) toward E-selectin binding and have also proposed, from molecular dynamics calculation, that their strong activities would depend on a possible formation of the type II and/or type II' beta-turn of compounds 3a,b (Tsukida, T.; Hiramatsu, Y.; Tsujishita, H.; Kiyoi, T.; Yoshida, M.; Kurokawa, K.; Moriyama, H.; Ohmoto, H.; Wada, Y.; Saito, T.; Kondo, H. J. Med. Chem. 1997, 40, 3534-3541). To clarify our hypothesis, we synthesized several analogues of compounds 3a,b and investigated their structure-activity relationships. As a result, it was indicated that the type II and/or type II' beta-turn conformation would be a comparatively tight form and would play important roles in favorable binding to E-selectin. These findings indicate that sLe(x) mimetics with type II and type II'-beta-turn dipeptides could be a useful methodology for the design of an active selectin blocker.
• Studies on Selectin Blockers. 5. Design, Synthesis, and Biological Profile of Sialyl Lewis x Mimetics Based on Modified Serine−Glutamic Acid Dipeptides
  作者：Takahiro Tsukida、Yasuyuki Hiramatsu、Hideki Tsujishita、Takao Kiyoi、Masahiro Yoshida、Kiriko Kurokawa、Hideki Moriyama、Hiroshi Ohmoto、Yukihisa Wada、Tadayuki Saito、Hirosato Kondo

  DOI：10.1021/jm970262k

  日期：1997.10.1

  rationally designed a sLe(x) mimetic based on molecular modeling, synthesized type II and type II' beta-turn dipeptides (3a,b), and evaluated their biological profiles both in vitro and in vivo. Against E-selectin-sLe(x) binding, the type II beta-turn dipeptide L-Ser-D-Glu 3a (IC50, 13 microM) and the type II' beta-turn dipeptide D-Ser-L-Glu 3b (IC50, 5.5 microM) were 20-100-fold more potent blockers than

  我们基于分子模型合理设计了sLe（x）模拟物，合成了II型和II'型β-转二肽（3a，b），并在体外和体内评估了它们的生物学特性。针对E-选择素-sLe（x）结合，II型β-转二肽L-Ser-D-Glu 3a（IC50，13 microM）和II'β-转二肽D-Ser-L-Glu 3b（ IC50（5.5 microM）比sLe（x）（1; IC50，600 microM）和3'-硫酸化Le（x）类似物（2; IC50，280 microM）强效阻滞剂高20-100倍。另一方面，其他立体异构体（例如L-Ser-L-Glu 3c和D-Ser-D-Glu 3d）是非常弱的阻滞剂，3c，d的IC50> 1000 microM。相对于P-和L-选择素，尽管化合物3a-d的立体化学差异很大，但二肽3a-d的阻滞剂均比sLe（x）或化合物2强。在小鼠模型中，化合物3b提供了针对免疫球蛋白E介导的皮肤反